Table 1. Baseline Characteristics of All Treated Patients.

Characteristic	Dose Level 1 (40 mg BID)	Dose Level 2 (80 mg BID)	Dose Level 3 (120 mg BID)	Dose Level 4 (160 mg BID)	All Dose Levels
	N = 3	N = 6	N = 6	N = 7	N = 22
Age – yr
Median	65	57	59	56	58
Range	62-86	50-75	40-78	42-74	40-86
Sex – no (%)
Male	2 (66)	0	3 (50)	3 (43)	8 (36)
Female	1 (33)	6 (100)	3 (50)	4 (57)	14 (63)
Ethnicity –no (%)
Caucasian	1 (33)	5 (83)	4 (66)	5 (71)	15 (68)
African American	2 (66)	1 (17)			3 (14)
Asian	0	0	1 (17)	1 (14)	2 (9)
Hawaiian/Pacific Islander	0	0	0	1 (14)	1 (4)
Mixed Race	0	0	1 (17)	0	1 (4)
ECOG performance status – no (%)
0	0	0	3 (50)	2 (29)	5 (23)
1	3 (100)	6 (100)	3 (50)	5 (71)	17 (77)
Primary Site of Disease –no (%)
Colon	1 (33)	0	0	3 (43)	4 (18)
Ovary	0	4 (66)	2 (33)	1 (14)	7 (32)
Peritoneal Mesothelioma	1 (33)	0	0	0	1 (4)
Peritoneal low-grade adenomucinous	1 (33)	0	0	0	1 (4)
Urachus	0	1 (17)	0	0	1 (4)
Pancreas	0	1 (17)	0	0	1 (4)
Stomach	0	0	1 (17)	0	1 (4)
Appendix	0	0	1 (17)	0	1 (4)
Fallopian Tube	0	0	1 (17)	0	1 (4)
Small Bowel	0	0	1 (17)	0	1 (4)
Duodenum	0	0	0	1 (14)	1 (4)
Cholangiocarcinoma	0	0	0	2 (29)	2 (9)
Disease Stage –no (%)
II	0	0	1 (17)	0	1 (4)
III	0	0	0	1 (14)	1 (4)
IV	3 (100)	6 (100)	5 (83)	3 (43)	17 (77)
Unknown	0	0	0	3 (43)	3 (14)
Prior Therapies - no
1	2 (66)	3 (50)	1 (17)	2 (29)	8 (36)
2-3	0	0	3 (50)	5 (71)	8 (36)
4 or more	1 (33)	3 (50)	2 (33)	0	6 (27)